• 1. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 2. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 5. Excited state characterization of carbonyl containing carotenoids: a comparison between single and multireference descriptions?
  Riccardo Spezia,Stefan Knecht,Benedetta Mennucci Phys. Chem. Chem. Phys., 2017,19, 17156-17166

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Fluorobenzenes

Recent Advances in the Study of 3-Bromo-5-(4-fluorophenyl)isoxazole (CAS: 903130-97-2)

3-Bromo-5-(4-fluorophenyl)isoxazole (CAS: 903130-97-2) is a heterocyclic compound that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound, characterized by its isoxazole core and halogenated phenyl substituent, has been explored for its pharmacological properties, particularly in the context of kinase inhibition and anti-inflammatory activity. Recent studies have focused on its synthesis, structural modifications, and biological evaluations, shedding light on its therapeutic potential.

A recent study published in the Journal of Medicinal Chemistry investigated the role of 3-Bromo-5-(4-fluorophenyl)isoxazole as a scaffold for developing selective kinase inhibitors. The researchers utilized a structure-activity relationship (SAR) approach to modify the compound's core structure, leading to the identification of derivatives with enhanced inhibitory activity against specific kinases implicated in cancer progression. The study highlighted the compound's ability to bind to the ATP-binding site of kinases, making it a promising candidate for further optimization.

In another study, researchers explored the anti-inflammatory properties of 3-Bromo-5-(4-fluorophenyl)isoxazole. The compound was found to modulate the NF-κB signaling pathway, a key regulator of inflammatory responses. In vitro and in vivo experiments demonstrated that the compound significantly reduced the production of pro-inflammatory cytokines, such as TNF-α and IL-6, suggesting its potential as a lead compound for developing novel anti-inflammatory agents. The study also emphasized the compound's favorable pharmacokinetic profile, including good oral bioavailability and metabolic stability.

The synthesis of 3-Bromo-5-(4-fluorophenyl)isoxazole has also been a focus of recent research. A team of chemists developed a novel, scalable synthetic route that improved the yield and purity of the compound. The new method involved a one-pot cyclization reaction, which significantly reduced the number of steps and minimized the use of hazardous reagents. This advancement is expected to facilitate the large-scale production of the compound for further pharmacological studies.

Despite these promising findings, challenges remain in the development of 3-Bromo-5-(4-fluorophenyl)isoxazole as a therapeutic agent. Issues such as off-target effects and potential toxicity need to be addressed through comprehensive preclinical studies. Future research directions may include the exploration of additional structural modifications to enhance selectivity and efficacy, as well as the evaluation of the compound's potential in combination therapies.

In conclusion, 3-Bromo-5-(4-fluorophenyl)isoxazole (CAS: 903130-97-2) represents a versatile scaffold with significant potential in drug discovery. Recent studies have elucidated its pharmacological properties and synthetic accessibility, paving the way for its further development as a therapeutic agent. Continued research efforts will be essential to fully realize its clinical potential and address existing challenges.

• 56045-65-9(Isoxazole, 3-bromo-5-(4-chlorophenyl)-)
• 138716-37-7(5-(4-Fluorophenyl)isoxazole)
• 387358-55-6(5-(3-Fluorophenyl)isoxazole)
• 874800-58-5(5-(3,5-Difluorophenyl)isoxazole)
• 10557-74-1(3-Bromo-5-phenyl-1,2-oxazole)
• 1159976-78-9(4-(3-Bromo-1,2-oxazol-5-yl)pyridine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)